Oxaliplatin-Induced Fever and Release of IL-6
暂无分享,去创建一个
[1] P. Breton,et al. Anaphylactic Reaction to Oxaliplatin: A Case Report , 1999, American Journal of Gastroenterology.
[2] C. Miki,et al. Serum interleukin‐6 level reflects the tumor proliferative activity in patients with colorectal carcinoma , 1999, Cancer.
[3] L. Wiseman,et al. Oxaliplatin: a review of its use in the management of metastatic colorectal cancer. , 1999, Drugs & aging.
[4] S. Piperno-Neumann,et al. Anaphylaxis after oxaliplatin. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] W. Scheithauer,et al. Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] T. Taguchi,et al. [Phase I clinical study of oxaliplatin]. , 1998, Gan to kagaku ryoho. Cancer & chemotherapy.
[7] G. Luporini,et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum , 1998 .
[8] C. Tournigand,et al. Severe anaphylactic reactions to oxaliplatin. , 1998, European journal of cancer.
[9] J. Misset. Oxaliplatin in practice. , 1998, British Journal of Cancer.
[10] M. Marty,et al. Pharmacokinetics and safety profile of oxaliplatin. , 1998, Seminars in oncology.
[11] Misset Jl. Oxaliplatin in practice. , 1998 .
[12] G. Luporini,et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. , 1998, European journal of cancer.
[13] E. Raymond,et al. [Oxaliplatin: the first DACH platinum in clinical practice]. , 1997, Bulletin du cancer.
[14] G. Welzl,et al. Regulated plasma levels of colony‐stimulating factors, interleukin‐6 and interleukin‐10 in patients with acute leukaemia and non‐Hodgkin's lymphoma undergoing cytoreductive chemotherapy , 1996, British journal of haematology.
[15] M. Björkholm,et al. Monitoring of endotoxin, interleukin‐6 and C‐reactive protein serum concentrations in neutropenic patients with fever , 1995, European journal of haematology.
[16] S. Steinshamn,et al. Soluble tumour necrosis factor receptors, tumour necrosis factor and interleukin‐6 in serum in granulocytopenic patients with fever , 1995, British journal of haematology.
[17] K. Pulkki,et al. Endotoxin, interleukin-6 and phospholipase-A2 as markers of sepsis in patients with hematological malignancies. , 1995, Scandinavian journal of infectious diseases.
[18] W. Graninger,et al. Release of TNF alpha and IL6 from human monocytes infected with Mycobacterium kansasii: a comparison to Mycobacterium avium. , 1994, Infection.
[19] A. Reinberg,et al. Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane(trans-1)oxalatoplatinum(II) in mice. , 1989, Cancer research.
[20] C. Kumana,et al. Fulminant hyperpyrexia induced by bleomycin. , 1989, Postgraduate medical journal.
[21] G. Jacoby,et al. Fever of undetermined origin. , 1973, The New England journal of medicine.